FDA rejects Summit Therapeutics' ivonescimab for lung cancer
The FDA has denied approval for Summit Therapeutics' ivonescimab to treat a specific type of lung cancer. The agency stated that the drug failed to demonstrate a statistically significant overall survival benefit, blocking its entry into the U.S. market despite its prior availability in China.

Original image temporarily unavailable
Rejection Details
Summit Therapeutics faced a setback as the FDA issued a complete response letter denying approval for its PD-1xVEGF bispecific antibody, ivonescimab, targeting EGFR-mutated non-small cell lung cancer after TKI inhibitor treatment. The regulatory agency argued that although the drug improved progression-free survival in the Phase 3 HARMONi trial, the absence of a statistically significant overall survival benefit means the therapy lacks a positive benefit-risk profile in its current form.
Industry Context
Ivonescimab, originally developed and partnered through China's Akeso where it became available in 2024, has drawn massive attention from major pharmaceutical companies and analysts who viewed it as a potential blockbuster backbone in oncology. Despite presenting updated global data showing slight overall survival benefits earlier, Summit must now re-evaluate its path forward for this indication while continuing trials in other cancer types.
View selection rationale
Importance 79/100
About this brief
- Content type
- News summary
- Source type
- Publisher report
- Original source
- BioSpace Drug Development ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.